|1.||Picano, Eugenio: 34 articles (06/2015 - 04/2002)|
|2.||Cortigiani, Lauro: 20 articles (06/2015 - 07/2002)|
|3.||Sicari, Rosa: 18 articles (06/2015 - 02/2003)|
|4.||Rigo, Fausto: 15 articles (06/2015 - 11/2003)|
|5.||Gherardi, Sonia: 14 articles (06/2015 - 08/2005)|
|6.||Bigi, Riccardo: 13 articles (05/2012 - 07/2002)|
|7.||Diener, Hans-Christoph: 13 articles (01/2012 - 01/2005)|
|8.||Picano, E: 12 articles (12/2003 - 01/2000)|
|9.||Bovenzi, Francesco: 11 articles (06/2015 - 02/2006)|
|10.||Galderisi, Maurizio: 9 articles (07/2014 - 07/2002)|
09/15/1998 - "The sustained release dipyridamole produced a significant risk reduction of 16% for stroke, 15% for stroke and/or death but no significant reduction of mortality. "
07/01/2008 - "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition. "
11/01/2013 - "A recent review discussed results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extended release dipyridamole in secondary stroke prevention. "
07/01/2008 - "The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention. "
07/01/2008 - "Based on the results from these 2 large, randomized trials, ASA + dipyridamole was more effective than ASA monotherapy as first-line therapy for secondary stroke prevention in these patients with a history of minor stroke or TIA of noncardioembolic etiology."
|2.||Coronary Artery Disease (Coronary Atherosclerosis)
10/01/1995 - "In patients with chronic coronary artery disease and a low incidence of cardiac events, dipyridamole echocardiography was effective in prognostic stratification, and positive low work load exercise ECG results were a reliable predictor of subsequent events. "
07/15/1992 - "Intravenous dipyridamole planar thallium-201 imaging is a safe and effective test for detection and prognosis of coronary artery disease (CAD) in the general population. "
03/01/1997 - "Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease."
02/01/1992 - "To evaluate the efficacy of stress technetium-99m MMI (N-2-methoxy-2-methyl propyl isonitrile) myocardial perfusion scintigraphy (Tc-99m MMI) using intravenous dipyridamole for detection of coronary artery disease (CAD), we collected 66 cases (53 men, 13 women, aged 40-79 years old) between Sept. "
02/01/1988 - "Thus, dipyridamole cardiac imaging is helpful in the diagnosis of coronary artery disease and in risk stratification."
12/01/1993 - "Dipyridamole echocardiography was well tolerated by elderly patients and proved to be very effective in prognostic stratification early after uncomplicated acute myocardial infarction, even when only survival was considered."
09/01/1997 - "Echocardiographic imaging during dipyridamole infusion is superior to sestamibi scintigraphy for predicting events after uncomplicated myocardial infarction."
03/01/1990 - "We have not found dipyridamole to be effective in the dog with coronary artery constriction and find no substantial evidence that it is effective in preventing myocardial infarction in man. "
11/15/2010 - "No previous study has assessed the possible role of dipyridamole for treatment of no-reflow during acute myocardial infarction (AMI). "
05/01/2010 - "Three trials included the endpoint of myocardial infarction in patients receiving ER dipyridamole. "
|4.||Myocardial Ischemia (Ischemic Heart Diseases)
03/01/1991 - "Thus, evaluation of early washout ratios (WR-25) after dipyridamole injection is a valuable method to increase sensitivity in assessing regional myocardial perfusion abnormality and is helpful in detection of ischemic heart disease, even with multivessel disease."
08/01/2001 - "Dipyridamole nuclear myocardial perfusion test is a safe and effective alternative to exercise nuclear perfusion testing for detecting myocardial ischemia. "
05/01/2010 - "One randomized controlled trial evaluated the efficacy of ER dipyridamole in patients with preexisting ischemic heart disease and found no evidence of increased risk of cardiac events in this population. "
01/01/1996 - "In response to dipyridamole introduction improved myocardial perfusion was registered in 4 out of 6 patients, 1 patient showed signs of transient myocardial ischemia, 1 patient had stable defects of myocardial blood supply. "
07/01/2002 - "Study aim was the prospective assessment of the impact of dipyridamole-induced myocardial ischemia on the signal-averaged ECG. "
03/01/1997 - "Results for sensitivity (89%) and negative predictive value (83%) in group 3 were significantly better than those in group 2 (71% [p = 0.03] and 56% [p = 0.002], respectively) and not significantly different from those in group 1. The polar maps of 20 patients studied with an without dipyridamole at the same exercise level revealed a significantly greater extent of ischemia in each territory and in a global assessment (19 + 20% vs. 8 + 11%, p < 0.0001) when dipyridamole was administered during physical exercise. "
08/01/1989 - "The increase in rate-pressure product (RPP = mm Hg x beats/min x 100) measured during the exercise stress test in the patients in group I was significantly greater than that determined during dipyridamole-induced ischemia (204 +/- 41 versus 145 +/- 33, p less than 0.01). "
06/01/1983 - "Rapid atrial pacing performed before and at 60, 90, and 120 minutes after dipyridamole failed to demonstrate any significant reduction in pacing threshold or evidence of increased ischemia after dipyridamole. "
06/01/2010 - "The aim of this study was to compare the feasibility and diagnostic accuracy of high-volume rate 3DE with state-of-the-art two-dimensional echocardiography (2DE) in detecting ischemia during dipyridamole-induced stress (DipSE). "
06/01/2010 - "This study tries to evaluate the prevalence and significance of ECG changes after dipyridamole infusion and their relation to ischemia in myocardial perfusion single-photon emission computed tomography (SPECT). "
|1.||Aspirin (Acetylsalicylic Acid)
|3.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|3.||Renal Dialysis (Hemodialysis)
|4.||Prostheses and Implants (Prosthesis)
|5.||Angioplasty (Angioplasty, Transluminal)